Kraeutler Matthew J, Mitchell Justin J, Chahla Jorge, McCarty Eric C, Pascual-Garrido Cecilia
Department of Orthopedics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Gundersen Health System, Department of Sports Medicine, La Crosse, Wisconsin, USA.
Orthop J Sports Med. 2017 Jan 19;5(1):2325967116680815. doi: 10.1177/2325967116680815. eCollection 2017 Jan.
Osteoarthritis (OA) after a partial or total meniscectomy procedure is a common pathology. Because of the high incidence of meniscectomy in the general population, as well as the significant burden of knee OA, there is increasing interest in determining methods for delaying postmeniscectomy OA. Biological therapies, including mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and platelet-rich plasma (PRP), have been proposed as possible therapies that could delay OA in this and other settings. Several studies in various animal models have evaluated the effect of injecting MSCs into the knee joints of animals with OA induced either by meniscal excision with or without anterior cruciate ligament transection. When compared with control groups receiving injections without progenitor cells, short-term benefits in the experimental groups have been reported. In human subjects, there are limited data to determine the effect of biological therapies for use in delaying or preventing the onset of OA after a meniscectomy procedure. The purpose of this review is to highlight the findings in the presently available literature on the use of intra-articular implantation of MSCs postmeniscectomy and to offer suggestions for future research with the goal of delaying or treating early OA postmeniscectomy with MSCs.
部分或全半月板切除术后的骨关节炎(OA)是一种常见的病理情况。由于普通人群中半月板切除术的高发生率,以及膝关节OA的沉重负担,人们对确定延缓半月板切除术后OA的方法越来越感兴趣。生物疗法,包括间充质干细胞(MSC)、诱导多能干细胞(iPSC)和富血小板血浆(PRP),已被提议作为可能延缓这种及其他情况下OA的疗法。在各种动物模型中的多项研究评估了将MSC注射到通过半月板切除或同时切断前交叉韧带诱导OA的动物膝关节内的效果。与接受无祖细胞注射的对照组相比,已报道实验组有短期益处。在人类受试者中,确定生物疗法用于延缓或预防半月板切除术后OA发作效果的数据有限。本综述的目的是突出目前关于半月板切除术后关节内植入MSC的可用文献中的研究结果,并为未来研究提供建议,目标是用MSC延缓或治疗半月板切除术后的早期OA。